Imago BioSciences
IMGO
IMGO was delisted on the 10th of January, 2023.
65 hedge funds and large institutions have $478M invested in Imago BioSciences in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 4 closing their positions.
114% more capital inflows, than outflows
Capital inflows: $20.5M | Capital outflows: $9.6M
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
28% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 18
5% more funds holding
Funds holding: 62 → 65 (+3)
1.87% more ownership
Funds ownership: 92.27% → 94.15% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.72M |
| 2 |
Soleus Capital Management
Greenwich,
Connecticut
|
+$3.45M |
| 3 |
BlackRock
New York
|
+$3.18M |
| 4 |
MPAM
Monarch Partners Asset Management
Boston,
Massachusetts
|
+$2.42M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Woodline Partners
San Francisco,
California
|
-$3.49M |
| 2 |
Goldman Sachs
New York
|
-$3.16M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$848K |
| 4 |
Trexquant Investment
Stamford,
Connecticut
|
-$429K |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$406K |
IMGO Hedge Fund Activity: Q3 2022 in Review
65 of the 5,833 institutional investors tracked by Wall St. Rank reported a position in Imago BioSciences (IMGO) for Q3 2022, worth a combined $478M — up 15% from $417M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new IMGO positions and 4 closed out — a net gain of 2 holders — while 23 added to existing stakes and 18 trimmed.
The largest buyer was Vanguard Group, adding an estimated $3.72M. The largest seller was Woodline Partners, cutting an estimated $3.49M.
- 65 institutional investors held Imago BioSciences (IMGO) as of Q3 2022, up from 62 in Q2 2022.
- Funds reported $478M of Imago BioSciences stock for Q3 2022, up 15% quarter-over-quarter.
- 6 funds opened new Imago BioSciences positions in Q3 2022 and 4 closed out, a net change of +2 holders.
- The largest Imago BioSciences buyer in Q3 2022 was Vanguard Group, an estimated $3.72M added.
- The largest Imago BioSciences seller in Q3 2022 was Woodline Partners, an estimated $3.49M sold.
Based on aggregated 13F filings for Q3 2022.